Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMP2-loaded dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
01
Overview
LMP2-loaded dendritic cell vaccine is an autologous cellular immunotherapy designed to treat Epstein-Barr virus (EBV)-positive lymphomas, including Hodgkin and non-Hodgkin lymphoma. Developed by Dr. David Rizzieri at Duke University, the vaccine consists of a patient's own dendritic cells that have been loaded with the EBV latent membrane protein 2 (LMP2) antigen. This approach aims to prime the immune system to recognize and destroy tumor cells expressing EBV proteins, particularly in patients who have undergone autologous stem cell transplantation. In clinical studies, the vaccine is often co-administered with DUK-CPG-001, a Toll-like receptor 9 (TLR9) agonist that serves as an adjuvant to enhance the vaccine's immunogenicity and the resulting T-cell response.
- Other names
- LMP2A-loaded conventional DC vaccineLMP-2A-loaded conventional DC vaccineLMP 2A-loaded conventional DC vaccineEBV-derived LMP2-loaded dendritic cell vaccineLMP2-loaded DC vaccineLMP-2-loaded DC vaccineLMP 2-loaded DC vaccine
02
Targets
PSMB9 (Immunoproteasome subunit beta type-1i)
Beyond the preview
Go deeper on LMP2-loaded dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMP2-loaded dendritic cell vaccine.